Lankenau Heart Institute team completes region’s first procedure to clear blocked coronary stent
Despite special drug coatings on stents, previously opened arteries can block up again in 5–10% of patients. The AGENT™ drug-coated balloon is a new minimally invasive option to prevent recurrence.
Wynnewood, PA — In a medical milestone for the Philadelphia region, a cardiac team at Lankenau Heart Institute, part of Main Line Health, has successfully completed the area’s first procedure using a new drug-coated balloon to clear a blocked stent previously placed in a treated artery.
More than 400,000 patients undergo percutaneous coronary intervention (PCI), also called angioplasty, to open blocked arteries every year. The procedure often is followed by placement of a stent: a small wire mesh coated with medicine to help keep the artery open. However, scar tissue can still gradually develop inside the stent in 5–10% of patients, causing the vessel to narrow again.
Interventional cardiologists Sarang Mangalmurti, MD, and Timothy Shapiro, MD, last month became the first in the region to treat a patient with this latest technology, which was implanted through a minimally invasive procedure. After reopening the coronary artery, they inserted the AGENT™ Drug-Coated Balloon through a catheter to deliver a drug called paclitaxel to the vessel wall to prevent re-narrowing. Data from a clinical trial enrolling 600 patients showed the drug-coated balloon to be more effective than an uncoated balloon, with the U.S. Food and Drug Administration earlier this year approving the device. The AGENT balloon has been used to treat more than 100,000 patients in other countries.
“The AGENT drug-coated balloon is a game changer in treating a problem that has challenged interventional cardiologists for decades,” said William Gray, MD, System Chief of Cardiovascular Diseases and Co-Director of the Lankenau Heart Institute. “This device is a significant innovation that addresses the stubborn problem of restenosis of stented coronary arteries. We strive to give our patients the most advanced care, and the AGENT balloon is a cutting-edge option that we’re proud to make available to them.”
As with any heart blockage, patients with restenosis may experience chest pain, shortness of breath, nausea, weakness, irregular or fast heartbeat and sweating.
“It is exciting for us to have been the first health system in the region to use the AGENT drug-coated balloon,” Dr. Shapiro said. “Traditional therapies besides uncoated balloon PCI include placing another layer of metal stents and radiation. Avoiding those options when possible is a real step forward.”
Dr. Mangalmurti said paclitaxel is a potent anti-scar tissue drug that reduces the chance of the stent clogging again. “It’s an important advance,” he said. “When we clear a blocked stent, we don’t want to have to keep bringing the patient back again for more procedures. Importantly, results from the AGENT trial indicate additional benefits to other treatment options, including a reduced risk of clotting and heart attack.”
About Lankenau Heart Institute
The Lankenau Heart Institute is Main Line Health's premier comprehensive cardiovascular medicine and surgery program. Lankenau Heart Institute brings together the clinical expertise of all four Main Line Health acute care hospitals and both the employed and community cardiology practices to ensure that patients receive a level of quality, service and experience that is unparalleled in the region. Through the systemwide coordination of services, Lankenau Heart Institute delivers preventive, diagnostic, therapeutic and rehabilitative cardiovascular services at each of our locations including Lankenau Medical Center, Bryn Mawr Hospital, Paoli Hospital and Riddle Hospital.
Lankenau Heart Institute continues to be an innovator in the use of beating-heart techniques and robotic-assisted procedures for coronary artery revascularization, minimally invasive and transcatheter approaches for valve repair and replacement, complex aortic surgery and heart rhythm disorders. With our growing experience and focus on minimally invasive techniques, Lankenau Heart Institute has expanded participation in clinical trials year after year. Our physicians are frequently invited to participate in clinical/medical device trials, many of which are designed to facilitate the use of minimally invasive approaches and procedures.
With a collaborative team of expert consultative cardiologists, interventional cardiologists, electrophysiologists, cardiovascular surgeons and specially trained advance practice nurses and technologists, Lankenau Heart Institute is dedicated to managing and treating patients with simple to complex cardiovascular disease, including heart failure, aortic disease, coronary and peripheral vascular disease, lipid and genetic abnormalities, heart rhythm disorders and valve disease. Our team of cardiologists and cardiac and vascular specialists provide patients and their families with expert cardiovascular care, close to home.